Jasper Therapeutics CFO Herb Cross to resign, interim officers named
Cross's resignation takes effect October 9, 2026, with CEO Jeet Mahal, VP Finance Rick Ruiz, and COO Matthew Ros filling interim finance and secretary roles.
SEC filing
Latest
6 stories
Monday, September 28
Wednesday, August 26
Jasper Therapeutics receives Nasdaq notice over stockholders' equity shortfall
The company has until October 5, 2026 to submit a plan addressing the deficiency, and is counting on a preferred stock conversion vote to fix it.
SEC filing
Friday, August 14
Jasper Therapeutics reports Q2 2026 results after closing Kira Pharmaceuticals merger
Jasper closed its acquisition of Kira Pharmaceuticals in July, raised $132 million in a concurrent private placement, and laid out 2026-2027 milestones for its three lead programs.
SEC filing
Tuesday, August 4
Jasper Therapeutics discloses $132 million private securities offering in SEC filing
A Form D filed August 4, 2026 shows Jasper Therapeutics sold $131,999,611 in equity securities to 40 investors under a Rule 506(b) exemption.
SEC filing
Thursday, July 16
Jasper Therapeutics completes all-stock merger with Kira Pharmaceuticals, adds $132 million PIPE
The combined company gains Kira's complement and B-cell programs alongside Jasper's briquilimab, with cash expected to last into the second half of 2028.
SEC filing
Jasper Therapeutics completes all-stock merger with Kira Pharmaceuticals
The combined company raised $132 million in a private placement and licensed out two complement assets to Mirador Therapeutics for $12 million upfront.
SEC filing